Compare BY & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | STOK |
|---|---|---|
| Founded | 1914 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2019 |
| Metric | BY | STOK |
|---|---|---|
| Price | $38.18 | $28.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $36.00 | ★ $39.20 |
| AVG Volume (30 Days) | 243.5K | ★ 679.1K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 5.09 | ★ 92.73 |
| EPS | ★ 1.73 | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $3.15 | $77.49 |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $25.57 | $20.32 |
| 52 Week High | $40.05 | $40.22 |
| Indicator | BY | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 41.29 |
| Support Level | $38.31 | $28.02 |
| Resistance Level | $39.48 | $33.61 |
| Average True Range (ATR) | 0.81 | 1.23 |
| MACD | -0.04 | -0.30 |
| Stochastic Oscillator | 37.21 | 14.14 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.